(Q42482385)

1 November 2017

Liposome-mediated gene transfer into human basal cell carcinoma (English)

1 reference

1 November 2017

1

1 reference

1 November 2017

3

Nickoloff BJ

1 reference

1 November 2017

Dam TN

2

1 reference

1 November 2017

Johnson TM

series ordinal

4

1 reference

1 November 2017

Nabel GJ

series ordinal

5

1 reference

1 November 2017

1 December 1999

1 reference

1 November 2017

1 reference

1 November 2017

6

1 reference

1 November 2017

12

1 reference

1 November 2017

1929-1935

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3301036

1 November 2017

0 references

cites work

Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Regression in basal cell carcinoma: an immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Treatment of neoplastic skin lesions with intralesional interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Impairment of thymus-derived lymphoid cell function in patients with basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Local immune response in basal cell carcinoma: characterization by transmission electron microscopy and monoclonal anti-T6 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Decreased lymphocyte blastogenic responses in patients with multiple basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Quantitative analysis of T6-positive Langerhans cells in human skin cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Immunologic Effects of Interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Direct gene transfer for treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Heterotransplantation of Human Basal Cell Carcinomas in “Nude” Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Transplantation of human basal cell carcinomas to athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Growth of human basal cell carcinomas transplanted to C57/Balb/C bgJ/bgJ nu/nu (beige-nude) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Cytokine therapeutics: lessons from interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Interferons and their actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Intracellular olfactory response of hippocampal neurons in awake, sitting squirrel monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

Nonmelanoma skin cancer in the United States: incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

7 January 2021

Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

7 January 2021

Intralesional interferon therapy for basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

7 January 2021

Treatment of basal cell carcinoma with intralesional interferon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301036

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301036

1 reference

Dimensions Publication ID

1 November 2017

0 references

1 reference